The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.
 
Qing Zhou
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Xiangqian Zheng
No Relationships to Disclose
 
Dapeng Li
No Relationships to Disclose
 
Dingzhi Huang
No Relationships to Disclose
 
Xingya Li
No Relationships to Disclose
 
Anwen Liu
No Relationships to Disclose
 
Xia Song
No Relationships to Disclose
 
Shanghua Jing
No Relationships to Disclose
 
Mingxia Wang
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Yongzhong Luo
No Relationships to Disclose
 
Yong Song
No Relationships to Disclose
 
Yanjun Mi
No Relationships to Disclose
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Yun Fan
No Relationships to Disclose
 
Haichuan Su
No Relationships to Disclose
 
Tao Huang
No Relationships to Disclose
 
Weiwei Ouyang
No Relationships to Disclose
 
Junyou Ge
No Relationships to Disclose